^
    Back
    Association details:
    Biomarker:MSLN expression
    Cancer:Mesothelioma
    Drug:gavocabtagene autoleucel (TC-210) (T-cell stimulant, Mesothelin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

    Excerpt:
    ...For Serous Ovarian Adenocarcinoma, patients must have confirmed positive MSLN expression on >/= 30% of tumor cells that are 1+, 2+, and/or 3+ by immunohistochemistry (IHC)....
    Trial ID:
    NCT03907852
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oncoimmunology
    Title:

    Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

    Published date:
    02/24/2023
    Excerpt:
    ...we report that mesothelin (MSLN)-specific TRuC-T cells (referred to as TC-210 T cells) potently kill MSLN+ tumor cells in vitro and efficiently eradicate MSLN+ mesothelioma, lung, and ovarian cancers in xenograft mouse tumor models.
    DOI:
    10.1080/2162402X.2023.2182058